Investor Presentaiton
mezigdomide (CELMOD)
Indication
Phase/Study
# of Patients
2L+ MM
Phase III SUCCESSOR-1
1
N = 810
Oncology
Hematology
Cell Therapy
Immunology
Cardiovascular
-
Mezigdomide 0.3, 0.6, 1.0 mg + bortezomib 1.3 mg/m2ª +
dex 20 mg (MeziVd)
•
Pomalyst 4 mg + bortezomib 1.3 mg/m2a + dex 20 mg - (PVD)
•
Design
Endpoints
Status
CT Identifier
Primary: PFS
Key secondary: OS
•
Recruiting
Projected data readout 2026
NCT05519085
ll Bristol Myers Squibb Q3 2023 Results
a BIW dosing; b QW dosing
2L+ MM
Phase III - SUCCESSOR-2
N = 575
Mezigdomide 0.3, 0.6, 1.0 mg + carfilzomib 56 mg/m2b + dex 40 mg b
- (Mezikd)
Carfilzomib 56 mg/m2a + dex 20 mga - (Kd)
Primary: PFS
Key secondary: OS
Recruiting
Projected data readout 2026
NCT05552976
Not for Product Promotional Use
39View entire presentation